October 6, 2023 :MedAlliance, a pioneering Swiss medical device startup, has been acquired by Cordis, a Johnson & Johnson company, in a landmark USD 1.135 billion deal. The acquisition, announced on October 6, 2023, is expected to close in the first half of 2024.
MedAlliance is a leader in developing and commercializing innovative medical devices for treating coronary artery disease (CAD). The company’s flagship product, the SELUTION SLR™ drug-eluting balloon (DEB), is a next-generation DEB superior to traditional DEBs in terms of safety and efficacy.
Cordis is a leading global provider of cardiovascular and neurovascular interventional solutions. The company’s portfolio includes products for treating CAD, peripheral artery disease, and stroke.
The acquisition of MedAlliance by Cordis is a significant development for the medical device industry. It is a testament to the strength of MedAlliance’s product pipeline and its potential to transform the treatment of CAD. The acquisition also validates the company’s innovative business model, which is focused on developing and commercializing next-generation medical devices.
The acquisition is also expected to benefit patients with CAD. Cordis’ global reach and resources will help accelerate the adoption of MedAlliance’s products and improve access to innovative treatments for patients worldwide.
The acquisition of MedAlliance by Cordis is a landmark event for the medical device industry and patients with CAD. The acquisition is expected to accelerate the adoption of MedAlliance’s innovative products and improve access to innovative treatments for patients around the world.
MedAlliance, a Swiss medical device company, has been bought by Cordis, a US medical device company, for USD 1.135 billion. This is a big deal because MedAlliance’s products are very good at treating heart disease. Cordis is a big company with many resources, so this deal should help MedAlliance’s products get to more patients around the world.